UB-421 Combine With Optimized Background Therapy Regimen in Multi-Drug Resistant HIV-1 Infection Patients
Status:
Not yet recruiting
Trial end date:
2022-05-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2, multi-center study, designed to evaluate the efficacy, safety, and
tolerability of UB-421 in conjunction with a failing existing ART regimen for 1 week and
optimized background therapy (OBT) for 24 weeks, respectively.